That wraps up our initial coverage of Tilray’s Q4 results. Thank you for stopping by!
Tilray’s Q4 beverage revenue grew 61% year over year to $105.6 million, surpassing cannabis, distribution, and wellness revenue during the quarter.
The BrewDog acquisition created a pro forma global beverage platform approaching $500 million in annual revenue. Tilray said it has already stabilized BrewDog and positioned the business for profitability while gaining access to its global brand, pub network, and hospitality platform.
The next test is margin improvement. Q4 beverage gross margin held steady at 38%, while the full-year figure declined to 36% from 39%. BrewDog is dramatically increasing Tilray’s scale, but management must now prove that scale can produce stronger returns.
Tilray Brands finished fiscal 2026 with record revenue of $915.5 million, up 11%, and management expects annual revenue to exceed $1 billion in fiscal 2027.
The company formally guided for adjusted EBITDA of $68 million to $75 million, representing double-digit growth from $61.1 million in fiscal 2026. At the midpoint, adjusted EBITDA would increase approximately 17%.
Tilray is entering the new year with four growing business segments and nearly $235 million in cash, restricted cash, and marketable securities. Delivering the $1 billion milestone alongside higher profitability would strengthen its transformation into a diversified global consumer-products company.
Tilray Brands just reported Q4 earnings, with shares initially up 4% following the report. Here are the key numbers:
Fiscal 2027 Guidance:
Adjusted EBITDA: $68 million to $75 million
Quick Read:
Tilray crushed revenue expectations and unexpectedly turned a profit, while management forecast double-digit adjusted EBITDA growth in fiscal 2027.
Beverage revenue surged 61% to $105.6 million, leading broad growth across all four operating segments and pushing annual revenue toward the $1 billion mark.
Tilray Brands (NASDAQ:TLRY) reports after the close with shares at $4.03, near the $3.80 52-week low.
To hit the reaffirmed $62M-$72M FY26 EBITDA range, Q4 revenue likely lands in the $187M-$197M zone versus $224.54M a year ago. Watch cannabis gross margin, which slid to 27% last quarter.
Options desks lean bullish: full-chain put/call ratio is 0.19. History warns of whipsaws, though. The Q4 FY25 beat still produced a -17.55% earnings-day drop. A clean EBITDA range hit plus an FY27 preview could spark a squeeze; any guidance cut likely retests $3.80.
Tilray Brands (NASDAQ:TLRY) Q3 FY26 results showed revenue of $206.73M versus $201.30M consensus, a 2.70% beat, though sales fell 22.96% YoY. Adjusted EPS of $0.02 missed the $0.07 estimate. Adjusted EBITDA rose 19% YoY to $10.71 million.
Management reaffirmed FY2026 adjusted EBITDA guidance of $62M to $72M, flagging Middle East tensions as a supply-chain risk.
Shares traded near $6.66 within an hour of release, closed at $6.55 the next day, and drifted to $6.75 a week later.
Key Takeaways: International cannabis revenue climbed 73%, Germany grew 43%, and Project 420 delivered $33 million in annualized savings, while beverage gross margin compressed to 32%. The BrewDog deal and 2027 Carlsberg partnership reset the beverage story.
With Tilray Brands (NASDAQ:TLRY) set to report Q4 earnings at 4:05 PM ET, here is a clean snapshot of the competing narratives heading into the release.
This live blog is being updated by Thomas Richmond, a 24/7 Wall St. contributor. You’ll get expert analysis of Tilray’s earnings.
Simply stay on this page, and new updates will appear below automatically. We expect Tilray to release earnings shortly after 4:05 p.m. ET.
Tilray Brands reports fiscal Q4 earnings after today’s close, with its $62-$72 million adjusted EBITDA target anchoring expectations.
International cannabis revenue climbed 73% year over year last quarter, but beverage sales declined, and gross margin slipped to 27%. Investors will now look for evidence that BrewDog can stabilize the beverage portfolio while international cannabis growth continues and management provides fresh commentary on U.S. rescheduling.
Tilray’s market capitalization has fallen to approximately $497.5 million after shares dropped 55.37% year to date. A clean EBITDA result, beverage stabilization, and early BrewDog traction could reframe Tilray as a scaled global consumer-products platform. Another stumble would reinforce concerns that cannabis growth cannot overcome margin compression, beverage weakness, and cash burn.
Live coverage has ended. The full story is below.
Tilray Brands (NASDAQ:TLRY) reports Q4 FY2026 results today at 4:05 PM ET, with the call scheduled for 4:30 PM ET. Shares sit at $4.03, and tonight’s report tests whether CEO Irwin Simon’s global platform lands within its reaffirmed FY2026 EBITDA guide.
Q3 FY2026 delivered a $206.73 million revenue beat, but adjusted EPS of $0.02 missed the $0.07 consensus by 71.43%. International cannabis grew 73% to $24.12M, and distribution hit a record $82.96M (+35%).
Beverage revenue declined, and consolidated gross margin slipped from 28% to 27%. TLRY is down 13.15% over the past month and 41.47% over the past year. Management reaffirmed FY2026 adjusted EBITDA of $62M to $72M, flagged Middle East geopolitical risk, and closed the BrewDog acquisition for approximately £40 million in cash.
| Metric | Q4 FY2026 Estimate | FY2026 Guide |
|---|---|---|
| Adjusted EPS | -$0.02 | Not disclosed |
| Adjusted EBITDA | Not disclosed | $62M to $72M |
Sell-side coverage is thin: 3 buys, 7 holds, with a $9.05 average target. TLRY trades at $4.00 per share today, at 0.58x sales and 0.3x book, framing tonight as an EBITDA credibility test more than an EPS event.
Tonight, I’ll be watching FY2026 adjusted EBITDA. CEO Simon held the $62M-$72M range through three quarters, so any walk-down tonight signals that Q3 execution slippage bled through Q4.
Beverage matters most. Q2 FY2026 revenue fell 21% with gross margin compressing from 40% to 31%. BrewDog closed post-quarter, so I’ll parse integration commentary and any early framing on the 2027 Carlsberg partnership.
International cannabis is another interesting story, with three straight quarters of accelerating growth at +10%, +36%, and +73%. Simon called Q3 the company’s “best quarterly net revenue in Company history.”
Cash is the pressure point. Free cash flow deteriorated to -$24.19M in Q3, and cash sits at $204.62M, down 29.15% YoY. Project 420 delivered $33M in annualized savings, so operating leverage should surface in the SG&A line.
Finally, listen for Simon’s U.S. federal rescheduling framing. He has tied Tilray’s U.S. beverage and medical optionality to that timeline in every recent call.
| Quarter | EPS Surprise | Day-of Move | 1-Day Move | 7-Day Move |
|---|---|---|---|---|
| Q3 FY2026 | -71.43% | -5.1% | +6.68% | +9.45% |
| Q2 FY2026 | Miss vs $0.00 | +0.55% | +1.31% | +3% |
| Q1 FY2026 | In line | +22.09% | -18.1% | -26.67% |
| Q4 FY2025 | +200% | -17.55% | +6.15% | +10.21% |
On average, shares moved -1% seven days after earnings over the past year.
Contact [email protected] for any questions or corrections.
Thomas Richmond is a financial writer and content strategist with 5+ years of experience covering stocks and financial markets. He has published over 250 articles focused on individual stock analysis, helping investors better understand business fundamentals, stock valuations, and long-term opportunities.
Thomas previously served as a Content Lead at TIKR, a stock research platform, where he helped scale the company’s blog to hundreds of articles per month and contributed to a weekly newsletter reaching more than 100,000 investors.
He specializes in breaking down complex companies into clear, actionable insights for everyday investors, with a focus on fundamentals-driven research.
His work has also been featured on platforms including Seeking Alpha and Sure Dividend.
Outside of work, Thomas enjoys weight lifting and soccer.
Tilray Brands (NASDAQ:TLRY) shares declined 4% in Wednesday morning trading, falling to around $6.20 after opening at $6.47. The drop came despite the company posting what it called a record Q3 result, leaving investors…
Tilray Brands (Nasdaq: TLRY) reports Q4 fiscal 2025 earnings after the market closes today. The cannabis and beverage company has been navigating volatile end-markets while executing a strategic shift toward higher-margin international medical cannabis…
Tilray Brands (NASDAQ: TLRY) reports fiscal Q1 2026 results before the market opens, following a transition year defined by consolidation and margin repair. The stock is up 275% over the past 6 months as…
Shares of Tilray Brands (NASDAQ:TLRY) are up roughly 10% in early Thursday trading, changing hands near $8.68 after the stock closed up 14% at $7.87 on Wednesday. The catalyst is growing speculation that the…
Cannabis investors have watched rescheduling euphoria ignite and incinerate capital at least four times since 2018, and a fresh DEA hearing is now on the calendar. The question is whether this cycle breaks the…
Tilray Brands' share price slipped after reporting a lackluster second-quarter results.
Tilray Brands made headlines after announcing its acquisition of eight craft beer and beverage brands from Anheuser-Busch.
From Hype to Hiccups in the Cannabis Craze Once hailed as the “next big thing,” cannabis stocks in 2018-2019 were the artificial intelligence stock darlings of their day, riding a wave of euphoria over…
Tilray surged Wednesday alongside Canopy Growth and Aurora Cannabis, but one number from 2026 tells a very different story about why today's rally leaves the real problem untouched.
